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In animals, the transcriptional responses to hypoxia primarily aim to increase oxygen delivery 
to cells and facilitate anaerobic glycolysis, in addition to other processes including cell matrix 
assembly, growth and apoptosis. The hypoxia-inducible transcription factors, HIF-lu and HIF­
2u, are key mediators of these responses. The HIF-us themselves are primarily regulated 
through the dual control mechanisms of stabilisation and transactivation, mediated by prolyl 
and asparaginyl hydroxylation. Despite high conservation in domain architecture and amino 
acid sequence, in addition to similarities in DNA binding and hydroxylation-dependent control, 
there are distinct biochemical and physiological differences between HIF-lu and HIF-2u, best 
demonstrated by the non-redundant nature of the HIF-u knockout mice. Very few mechanistic 
differences between HIF-lu and HIF-2u however are known, which cannot explain this non­
redundancy. The aim of this PhD thesis is therefore to determine novel mechanisms regulating 
HIF-lu and HIF-2u that may underlie these differential properties. 
To achieve this aim, a yeast two-hybrid screen was initially employed using a region ofHIF-2u 
possessing the highest sequence divergence with HIF-lu. The NF-KB Essential Modulator, 
NEMO, was identified as a HIF-2u, but not HIF-lu, interacting protein which was 
subsequently confirmed in mammalian cells by various pull down and immunoprecipitation 
methods. Furthermore, NEMO specifically increased HIF-2u activity at normoxia, both when 
overexpressed and at endogenous levels, via a mechanism consistent with the enhanced 
recruitment of the CBP / p300 coactivators. 
An additional strategy to analyse differential HIF-lu / 2u regulation was to compare their 02-
regulated stabilisation and transactivation across a number of mammalian cell lines. Although 
generally, the HIF-u proteins were stabilised and transcriptionally activated over a similar 02 
range, interesting cell-specific differences were apparent, both when comparing HIF-lu and 
HIF-2u and when comparing different cell-lines to each other. For example, iron chelation does 
not stabilise HIF-2u protein, although HIF-2u transactivation, and HIF-lu stabilisation and 
transactivation are strongly increased. Cell lines also display large differences in the 02-
responsiveness ofHIF-u transcriptional activation. 
In vitro, the HIF-2a C-terminal transactivation domain (C-TAD) is less efficiently 
hydroxylated by FIH-l than HIF-la. This would be expected to increase CBP / p300 
recruitment which parallels the increased activity of HIF-2a C-TAD compared with HIF-l a in 
cells. Interestingly, the residue immediately C-terminal to the hydroxy-asparagine differs 
between HIF-la and HIF-2a though is then fully conserved across species. In vitro 
hydroxylation and cell-based reporter assays were employed to identify this amino acid as an 
important, though not sole, contributing factor specifying the inherent differences in FIH-l 
mediated C-terminal hydroxylation. 
Work comprising this thesis identifies NEMO as a HIF-2a specific interacting and regulatory 
factor, in addition to uncovering further insights into the cell-specific nature of HIF-a 
regulation. This complements an emerging body of evidence demonstrating that multiple 
factors appear responsible for the differential regulation of HIF-la and HIF-2a that underlie 
their non-redundant functions. 
